Last update 24 Jun 2025

VMD-928

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
VMD 928
Target
TrkA
Action
antagonists
Mechanism
TrkA antagonists(Nerve growth factor receptor Trk-A antagonists)
Therapeutic Areas
NeoplasmsImmune System DiseasesNervous System Diseases+ [7]
Active Indication
Adenoid Cystic CarcinomaAdvanced Head and Neck CarcinomaAppendiceal Neoplasms+ [13]
Inactive Indication-
Originator Organization
VM Oncology LLC
Active Organization
VM Oncology LLC
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with VMD-928
NCT03556228
/ RecruitingPhase 1
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
100 Clinical Results associated with VMD-928
Login to view more data
100 Translational Medicine associated with VMD-928
Login to view more data
100 Patents (Medical) associated with VMD-928
Login to view more data
100 Deals associated with VMD-928
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenoid Cystic CarcinomaPhase 1
United States
VM Oncology LLC
08 Jun 2018
Advanced Head and Neck CarcinomaPhase 1
United States
VM Oncology LLC
08 Jun 2018
Appendiceal NeoplasmsPhase 1
United States
VM Oncology LLC
08 Jun 2018
Bladder CancerPhase 1
United States
VM Oncology LLC
08 Jun 2018
Breast CancerPhase 1
United States
VM Oncology LLC
08 Jun 2018
Esophageal CarcinomaPhase 1
United States
VM Oncology LLC
08 Jun 2018
LymphomaPhase 1
United States
VM Oncology LLC
08 Jun 2018
MesotheliomaPhase 1
United States
VM Oncology LLC
08 Jun 2018
Non-Small Cell Lung CancerPhase 1
United States
VM Oncology LLC
08 Jun 2018
Olfactory EsthesioneuroblastomaPhase 1
United States
VM Oncology LLC
08 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03556228 (ASCO 12021 | ASCO 22021)
ManualManual
Phase 1
Solid tumor | Lymphoma
TRKA Overexpression
20
tjwgrjygtf(kelaqbpshu) = The recommended phase 2 dose (RP2D) is 600 mg twice (1200 mg) per day. anrkvihfsp (wjaaowgikd )
View more
Positive
20 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free